DEF: Surrozen Sets 2026 Annual Meeting, Reveals Soaring Losses

Surrozen, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on May 13, 2026, to vote on director elections, auditor ratification, and executive compensation, while disclosing a significant increase in net losses.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on Wednesday, May 13, 2026, at 10:00 a.m. Pacific Time.
• Stockholders of record as of March 18, 2026, are entitled to vote, with 11,486,707 shares of common stock outstanding.
• Key proposals include the election of Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D. as Class II directors, ratification of Ernst & Young LLP as the independent auditor for 2026, and advisory votes on executive compensation and its preferred frequency (Board recommends one year).
• The company reported a net loss of $242 million for 2025, a substantial increase from $64 million in 2024.
• Despite increased losses, the Total Stockholder Return (TSR) for an initial $100 investment grew from $152.66 in 2024 to $240.43 in 2025.
• Executive compensation for 2025 included $2,819,017 for CEO Craig Parker, $1,518,919 for COO Charles Williams, and $1,286,981 for EVP Research Yang Li, Ph.D.
• Executive officers achieved 100% of corporate performance goals for 2025, resulting in full targeted bonuses.
• Audit fees billed by Ernst & Young LLP were $1,226,000 in 2025, up from $981,000 in 2024.
• The company completed initial and optional closings of a March 2025 private placement, raising $71.2 million and $3.3 million net proceeds, respectively, with a remaining $95.1 million contingent on FDA clearance for SZN-8141.
• Significant beneficial owners include entities affiliated with The Column Group (29.31%), TCG Crossover Management, LLC (11.76%), RA Capital Healthcare Fund, L.P. (9.99%), AI Biotechnology LLC (9.99%), 5AM Ventures VII, L.P (9.99%), and Venrock Healthcare Capital Partners (9.99%).
• Sublease income from Nura Bio, Inc. (a related party) was $0.7 million in 2025 and $0.4 million in 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as mixed. While the company successfully secured significant capital and reported a strong TSR, the substantial increase in net loss and the contingency of future funding on FDA clearance introduce considerable financial and operational uncertainty.

Positives

• The Board recommends the re-election of two experienced Class II directors, Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D., ensuring continuity in governance.
• The Board recommends the ratification of Ernst & Young LLP as the independent registered public accounting firm, indicating satisfaction with audit services and stability.
• Executive officers achieved 100% of corporate performance goals for 2025, leading to full targeted bonuses, suggesting strong internal operational execution.
• Total Stockholder Return (TSR) for a $100 investment increased significantly from $152.66 in 2024 to $240.43 in 2025, indicating positive market perception despite financial losses.
• The company successfully secured initial and optional tranches of a March 2025 private placement, raising $71.2 million and $3.3 million, demonstrating continued investor confidence.
• Sublease income from Nura Bio, Inc. contributed $0.7 million in 2025 and $0.4 million in 2024, reducing operating expenses.

Negatives

• Net loss significantly increased from $64 million in 2024 to $242 million in 2025, representing a substantial widening of losses.
• The second tranche of the March 2025 private placement, totaling $95.1 million, is contingent on FDA clearance of the Investigational New Drug Application (IND) for SZN-8141, introducing regulatory uncertainty for future funding.
• Director Tim Kutzkey, Ph.D. attended only 60% of Board meetings during his tenure in 2025.
• No directors attended the 2025 annual meeting of stockholders, which could be perceived as a lack of engagement.
• A Section 16(a) report for Dr. Kutzkey was filed late in December 2025, indicating a compliance lapse.

Risks

• The company's ability to access the remaining $95.1 million from the March 2025 private placement is contingent on FDA clearance of the Investigational New Drug Application (IND) for SZN-8141, posing a significant regulatory and funding risk.
• The substantial increase in net loss from $64 million in 2024 to $242 million in 2025 indicates a high cash burn rate, which could continue and impact financial sustainability.
• Broker non-votes on non-discretionary matters (Proposals 1, 3, and 4) could affect the outcome of these votes, as brokers lack authority to vote uninstructed shares.
• The terminated strategic research collaboration agreement with TCGFB, Inc. could signal challenges in forming or maintaining key R&D partnerships.
• Limitations of liability and indemnification provisions for directors and officers, while common, are unenforceable under federal securities laws for certain liabilities, potentially impacting the company's ability to attract and retain qualified personnel.

Future Outlook

The company expects the second closing for the remaining $95.1 million from the March 2025 private placement in 2026, contingent on FDA clearance of the Investigational New Drug Application for SZN-8141. These funds are intended to advance multiple ophthalmology programs through initial Phase 1 safety, tolerability, and efficacy studies.

Management Comments

• "Your vote is important to us. Please act as soon as possible to vote your shares." Craig Parker, President, Chief Executive Officer and Director.
• "On behalf of the Board of Directors and management, it is my pleasure to express our appreciation for your continued support." Craig Parker, President, Chief Executive Officer and Director.

Industry Context

StockSavvy.ai notes that the significant increase in net loss from 2024 to 2025 for Surrozen, Inc. is a concern, especially for a biotechnology company in the R&D phase where capital burn is expected but needs to be managed. However, the reported increase in Total Stockholder Return (TSR) suggests that market sentiment or specific pipeline developments might be offsetting the financial losses, potentially indicating investor confidence in future drug candidates or strategic direction, which is not uncommon in the high-risk, high-reward biotech sector. The reliance on FDA clearance for a substantial capital raise highlights the critical regulatory hurdles inherent in the industry.

Comparison to Industry Standards

• The reported TSR increase from $152.66 to $240.43 for a $100 investment, despite a widening net loss, suggests that Surrozen's stock performance may be outperforming some peers or reflecting specific positive pipeline news not detailed in this proxy. For example, while many early-stage biotech companies like Moderna (MRNA) or BioNTech (BNTX) experienced significant stock volatility during their R&D phases, a substantial TSR increase alongside increased losses could indicate strong investor belief in a specific drug candidate's potential, similar to how Vertex Pharmaceuticals (VRTX) saw significant gains during its cystic fibrosis drug development, even with initial losses.
• The net loss of $242 million in 2025, compared to $64 million in 2024, represents a substantial increase in cash burn. This level of loss is not unusual for a clinical-stage biotechnology company, but the rate of increase is notable. For instance, CRISPR Therapeutics (CRSP), another innovative biotech, reported net losses of $400 million in 2023, but this was often tied to specific R&D expenditures or clinical trial advancements. The filing does not provide context for the increased loss, making it difficult to assess if it aligns with accelerated program development or operational inefficiencies compared to peers like Beam Therapeutics (BEAM) or Intellia Therapeutics (NTLA), which also manage significant R&D costs.
• The successful initial and optional closings of the March 2025 private placement, raising $71.2 million and $3.3 million respectively, demonstrate continued investor confidence, particularly from major biotech investors like The Column Group, RA Capital, and Venrock. This is a positive signal, as securing capital is a constant challenge for development-stage biotechs. However, the contingency of the remaining $95.1 million on FDA clearance for SZN-8141 is a standard but significant hurdle, comparable to the financing challenges faced by companies like Sarepta Therapeutics (SRPT) during its early Duchenne muscular dystrophy drug development, where funding often hinged on regulatory milestones.

Management Changes

Corporate Governance

Related Party Transactions

• A strategic research collaboration agreement with TCGFB, Inc. (affiliated with The Column Group, a significant stockholder and where director Tim Kutzkey is a Managing Partner) was entered into in October 2024 and terminated in November 2025. TCGFB was to pay up to $6.0 million plus third-party costs and issued a warrant for 3.4 million shares of TCGFB common stock.
• The March 2025 private placement involved entities affiliated with The Column Group, which purchased 1,034,482 shares and 517,241 Series E Warrants in the first tranche, and committed to purchase 1,551,724 shares and 775,862 Series E Warrants in the second tranche.
• The April 2024 private placement involved entities affiliated with The Column Group (193,548 shares, 193,548 Series A Warrants, 210,526 Series B Warrants, 749,998 Series C Warrants, 749,998 Series D Warrants), CEO Craig Parker (1,474 shares, 1,474 Series A Warrants, 1,603 Series B Warrants, 5,712 Series C Warrants, 5,712 Series D Warrants), and COO Charles Williams (1,474 shares, 1,474 Series A Warrants, 1,603 Series B Warrants, 5,712 Series C Warrants, 5,712 Series D Warrants).
• A sublease agreement with Nura Bio, Inc. (where director Tim Kutzkey is chairman of the board and The Column Group is a significant stockholder) generated $0.7 million in sublease income in 2025 and $0.4 million in 2024.

Stakeholder Impact

• Shareholders: Will participate in key corporate governance decisions at the Annual Meeting, including director elections and executive compensation. Their investment is directly impacted by the company's financial performance (increased net loss, but also increased TSR) and the success of future capital raises.
• Employees: Executive compensation policies, including annual performance-based cash bonuses and equity incentive plans, are in place. The 2025 Equity Inducement Plan is specifically for newly hired employees, aiding in talent acquisition.
• Customers/Partners: The termination of the TCGFB research collaboration could impact future R&D efforts or partnership strategies, potentially affecting the development pipeline.
• Creditors: The company's ability to secure future funding, particularly the contingent second tranche of the 2025 PIPE, is crucial for its financial stability and ability to meet obligations.

Next Steps

• Stockholders will vote on director elections, auditor ratification, executive compensation, and the preferred frequency of executive compensation advisory votes at the Annual Meeting on May 13, 2026.
• The company expects FDA clearance for the SZN-8141 IND in 2026 to unlock the second tranche of the March 2025 private placement.
• The company plans to fund multiple ophthalmology programs through initial Phase 1 safety, tolerability, and efficacy studies.
• The Board and compensation committee will consider stockholder feedback on executive compensation.
• Stockholders can submit proposals for the 2027 Annual Meeting by December 2, 2026 (for inclusion in proxy materials) or between January 13, 2027, and February 12, 2027 (not for inclusion).

Key Dates

Recommendation

While Surrozen, Inc. demonstrated strong Total Stockholder Return (TSR) in 2025 and successfully secured substantial capital through private placements, the significant increase in net loss from $64 million in 2024 to $242 million in 2025 raises concerns about cash burn and operational efficiency. The contingency of a $95.1 million capital tranche on FDA clearance for SZN-8141 introduces a material regulatory risk. Investors should hold to monitor the company's progress on SZN-8141's IND clearance and observe whether the increased R&D expenditure translates into tangible pipeline advancements that can justify the widening losses and sustain the positive TSR trend.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Stockholder Vote, SEC Filing, Surrozen Inc., SRZN, Biotechnology, Financial Reporting, Equity Awards, Private Placement, FDA Clearance, SZN-8141, Net Loss, TSR